Drug Profile
GI 5005
Alternative Names: GI-5005; TarmogenLatest Information Update: 14 Sep 2015
Price :
$50
*
At a glance
- Originator GlobeImmune
- Class Antivirals; Hepatitis C vaccines
- Mechanism of Action Immunostimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 03 Nov 2010 GlobeImmune receives grants under the Federal Therapeutics Discovery Projects programme for GI 5005 development in Hepatitis C
- 30 Oct 2010 Efficacy data from a phase IIb trial (GI-5005-02) in Hepatitis C presented at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2010)
- 28 Oct 2010 GlobeImmune expands phase IIb trial (GI-5005-02) for treatment-naive Hepatitis C to include patients with IL28B T/T genotype